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ABSTRACT 
The unprecedented iridium-catalyzed asymmetric hydrogenation of N-allyl phthalimides to 
afford enantioenriched chiral amines bearing a β-methyl is presented. Recently developed Ir-
MaxPHOX are used as catalysts for this enantioselective transformation. The hydrogenation 
reaction has been studied in detail in order to find the optimal conditions. The mild reaction 
conditions and the feasibility of the removal of the phthalimido protecting group makes this 
process easily scalable and of interest for multiple synthetic applications. 
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Introduction 
Catalytic Asymmetric Hydrogenation 
Asymmetric hydrogenation of alkenes mediated by organometallic catalysts is a powerful tool 
for organic synthesis, both in academia and industry settings.
 [1,2]
 Furthermore, it is a simple 
and fully atom economical reaction. Although the reaction is simple, it provides synthetic 
intermediates or valuable hydrogenated compounds, which are of great interest for their use in 
the preparation of pharmaceutical or research materials. The impact of asymmetric 
hydrogenation is testified by the Nobel Prize in Chemistry awarded to some of the pioneers of 
asymmetric hydrogenation (Knowles and Noyori) in 2001. Among the many different existing 
ligands, phosphorous ones have proven very useful for these procedures.
[3]
 The ligand plays a 
vital role in the catalysis, as the ligand’s chirality can be transferred to the product. There is a 
wide range of P-based chiral ligands, which can be classified in three groups depending on 
where the chirality lies; on the P atom, on the backbone or on both the P atom and the 
backbone.
[4,5]
 Furthermore, among the P-based ligands we could, generalizing, differentiate 
two large main groups: the P,P and the P,N ligands.
[6,7]
 
The P,P based catalysts are built around two phosphorous atoms that coordinate the metal. 
With metals such as rhodium or ruthenium, these catalysts are often proficient in the 
hydrogenation of functionalized olefins (amides or carboxylic acids work well as coordinating 
groups, for example). However, when it comes to selectively hydrogenating minimally or 
even un-functionalized double bonds, these catalysts usually fail in providing sufficient 
asymmetric induction and reactivity. For these substrates, recently, P,N ligands based 
catalysts, coordinated to iridium, have emerged as a promising alternative to the other 
catalysts. Thus, the Pfaltz’s and Dieguez’s research groups have extensively investigated the 
iridium-catalyzed enantioselective hydrogenation reaction using un-functionalized olefins as 
substrates. In addition, they investigated also terminal alkenes bearing a neighboring group 
which belong to minimally functionalized olefins. The most common substrates available in 
the literature are limited to allylic alcohols, allylic acetates and allyl silanes. 
Frequently, for these procedures, the solvent is chosen accordingly; for P,P catalysts, 
coordinating solvents like alcohols are normally employed, while for the P,N type non-
coordinating solvents like dichloromethane are used. This is a classification that cannot be 
taken very strictly because there is a broad spectrum of compounds that lay in-between the 
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functionalized and the completely non-functionalized substrate distribution. It is important to 
understand that this approach as a rough classification, used to give a general overview on the 
topic. 
Iridium P,N complexes, Asymmetric Catalysis 
Iridium complexes with chiral P,N ligands are efficient catalysts for the enantioselective 
hydrogenation of un-functionalized alkenes.
[8,9]
 In this respect, they clearly distinguish 
themselves from chiral rhodium and ruthenium catalysts, which only perform well with 
substrates bearing a polar coordinating group next to the C=C bond.
[10,11,12]
 
The Crabtree’s catalyst 
During the 70’s, Crabtree designed the first P,N-Ir catalyst (Figure 1). This compound was 
both faster and more effective than its diphosphine analogs in the hydrogenation of non-
functionalized tri- and tetrasubstituted alkenes.
[13,14]
 This catalyst, before it undergoes 
hydrogen activation, is air stable. However, it did have a shortcoming; when the coordination 
with the alkene is weak, the active catalyst dimerizes and trimerizes, ending up forming 
inactive clusters.
[15]
 Consequently, high loadings were often required for full conversions. It 
does not induce enantioselectivity, being achiral. 
 
Figure 1 Crabtree’s catalyst; the first P,N-Ir catalyst. 
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The Pfaltz’s catalysts  
In 1997 Pfaltz and co-workers developed a chiral version of the Crabtree’s catalyst, the Ir-
PHOX (Figure 2).
[16]
 Unlike Crabtree’s catalyst, Pfaltz’s catalyst has a phosphinooxazoline 
molecule as ligand. Consequently, the P and the N metal-chelating units are bound together 
by a chiral C-backbone. This complex performs particularly well on the asymmetric 
hydrogenation of N-arylimines
[16]
 and non-functionalized tri- and tetrasubstituted alkenes.
[17]
 
However, as a hexafluorophosphate salt, it also exhibited the issue of deactivation by 
aggregation into inactive clusters when the coordination with the substrate is feeble.
[18]
 Up to 
3 mol% loading of the catalyst was often required. Pfaltz overcame this shortcoming by 
exchanging the counteranion for BArFˉ, a large, weakly coordinating counteranion.
[19]
 While a 
more coordinating counteranion like PF6ˉ might interfere with the alkene coordination to the 
metal, the BArFˉ counteranion does not hamper the coordination at all. Therefore, the catalyst 
is “virtually saturated with alkene” and the hydrogenation pathway clearly predominates over 
the deactivation by formation of inactive hydride-bridged trinuclear complexes.  
 
Figure 2 The Ir-PHOX catalyst; chiral P,N-Ir catalyst with BArF
‒
 as counteranion. 
 
Subsequently, Pfaltz reported in 2001 a new class of iridium complexes with 
phosphooxazoline ligands, the SerPHOX and the ThrePHOX.
[20]
 In comparison to the Ir-
PHOX, the phosphorous unit on these catalysts is attached next to the stereogenic center of 
the oxazoline moiety. 
Another quite interesting catalysts that Pfaltz developed in 2004 are the SimplePHOX (Figure 
3).
[21]
 As the name tells, the selling point is their very simple preparation. Reaction between a 
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chiral amino alcohol (obtained from an amino acid) and 2-hydroxy-2-methylpropionic acid 
affords the corresponding oxazonyl alcohol, direct precursor of the SimplePHOX ligand. 
 
Figure 3 The SerPHOX, the ThrePHOX and the SimplePHOX Ir catalysts. 
Pursuing of achieving a more similar coordination sphere to the Crabtree’s catalyst, Pfaltz 
developed another noteworthy type of catalysts derived from pyridine and quinoline (Figure 
4).
[22]
 These complexes proved to be useful in the asymmetric hydrogenation of purely alkyl-
substituted olefins and furans.
[23]
 
 
Figure 4 Pyridine and quinolines derived Pfaltz’s complexes. 
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The Andersson’s and Dieguez’s catalysts 
Andersson and co-workers, between 2004 and 2006,
[24,25,26]
 studied and developed new P,N 
ligands that contain a rigid bicyclic backbone and an oxazole or a thiazole moiety (Figure 5). 
A norbornane-oxazoline based ligand was also developed. These ligands, once coordinated to 
iridium, perform at the same level as the best oxazoline-based complexes. 
 
Figure 5 Andersson’s Ir-P,N catalysts. 
In 2009 Dieguez, Andersson and Borner joined forces to develop a library of up to 96 
phosphite oxazoline ligands.
[27]
 These ligands are formed out of a SerPHOX or ThrePHOX 
derived backbone plus different chiral biarylphosphinites (Figure 6). With Ir as metal and 
BArFˉ as counteranion, they hydrogenated for instance a series of aryl-alkyl substituted 
terminal alkenes with good results. 
 
Figure 6. Ir / Phosphite oxazoline catalyst library. 
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Other Ir-P,N catalysts 
Chiral P,N-Iridium catalysts have arisen a lot of interest from many research groups, 
prompting the disclosure of many complexes belonging to this class. Herein, few noteworthy 
examples are reported. 
Knochel,
[28]
 in 2003, developed another new pyridine-phosphine catalyst to hydrogenate 
methyl α-acetamidocinnamates with ee’s up to 97%, as shown in Figure 7. Zhou developed in 
2006 a new ligand that he named SIPHOX.
[29]
 This phosphine-oxazoline ligand contains a 
rigid and bulky spirobiindane backbone. Once coordinated to iridium, with BArFˉ as 
counteranion, the complex is efficient for example in the asymmetric hydrogenation of N-aryl 
imines. 
 
Figure 7 Knochel’s and Zhou’s Ir catalysts. 
Finally, Burgess reported in 2003 a new iridium catalyst.
[30]
 The catalyst contains the 
common oxazoline moiety and, although the P-group has been replaced by a heterocyclic 
carbene, it is worth to mention this complex (Figure 8). The catalyst has been used in the 
hydrogenation of bis and monoarylalkenes, allylic alchohols, enoates and more.
[31]
 
 
Figure 8 The Burgess’s catalyst. A N,Carbene-Ir complex. 
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Ir-MaxPHOX catalysts 
The Prof. Riera’s group developed a methodology to synthesize chiral aminophosphines by 
SN2@P reaction between an amine and the chiral synthon tert-butylmethylphosphinous acid 
borane. Applying this procedure, the synthesis of the MaxPHOX ligand and its coordination 
to iridium was reported (Figure 9). The complexation involves a 3-step procedure; first, there 
is the deprotection with neat pyrrolidine. This cyclic amine proved to be a better reagent for 
deprotection than, for example, the well-known DABCO basically due to purification issues. 
Once the phosphine is deprotected, the pyrrolidine can be removed under high vacuum. The 
borane protected pyrrolidine byproduct formed is not volatile, but it does not affect the 
procedure and can be purified straightforwardly at the end of the synthesis. The free ligand, 
under N2 atmosphere, is resolubilized with CH2Cl2 and then [IrCl(cod)]2 is added. After 1 h, 
NaBArF is added and the reaction is left stirring for another hour. The catalyst, with BArFˉ as 
counteranion, can be easily purified by chromatography on silica with hexanes / CH2Cl2.  
 
Figure 9 The 3 step procedure for the coordination of MaxPHOS with Ir. 
The Ir-MaxPHOX catalysts bear three independent chiral centers; one is the P unit and the 
other two are located in the C-backbone. Therefore, for one type of Ir-MaxPHOX catalyst 
(same substituents) there are four possible diastereoisomers, as shown in Figure 10. As the C-
backbone chiral groups can be easily changed (Ph, Bn, iPr, t-Bu, etc), the possible 
combinations are many. Hence, one of the strong points of this family of catalysts is the 
possibility to fine-tune the complex until the asymmetric catalytic process proceeds as 
desired.  
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Figure 10 There are four diastereoisomers for one Ir-MaxPHOX catalyst. The other 4 stereoisomers would be 
the corresponding enantiomers. 
 
Our group has used the Ir-MaxPHOX family to asymmetrically hydrogenate the following 
substrates (Figure 11): 
a) N-aryl imines 
b) N-alkyl imines 
c) Cyclic Enamides 
d) N-sulfonyl allylic amines 
 
Figure 11 Amine substrates used with Ir-MaxPHOX catalysts.
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Minimally functionalized olefins 
As mentioned, the alkenes used in asymmetric hydrogenation reactions can be classified in 
three different classes: un-functionalized, minimally functionalized and functionalized. The 
un-functionalized olefins are alkenes which do not have a coordinating group and their 
hydrogenated products give practically hydrocarbons (Figure 12, compounds A and B). On 
the other hand, the functionalized olefins are alkenes in which the double bound is conjugated 
with a coordinating group such as amides or carboxylic acids. Between these two classes 
there are the minimally functionalized olefins. Even if the double bound is conjugated with a 
polar neighboring group, this group does not have strong coordinating properties. For this 
reason this classification is not a “black and white” expression; so many alkenes fall into the 
“gray area”. 
The asymmetric hydrogenation of minimally functionalized olefins is a challenging field. 
Although these substrates are easy to hydrogenate, it is difficult to induce enantioselectivity 
since they lack coordinating groups that can bind the metal generating geometrically ordered, 
defined complexes. In this context, di-substituted terminal alkenes are an even more 
challenging substrate class than the more widely investigated trisubstituted olefins. In facts, 
regarding to terminal alkenes, only few examples can be found in the literature and, as 
mentioned above, most of these are limited to allylic alcohols, allylic acetates and allyl 
silanes.  
 
Figure 12 Examples of un-, minimally functionalized and functionalized olefins. 
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Pfaltz asymmetric hydrogenation of unfunctionalized olefins with Ir-PHOX 
catalysts 
As above mentioned, Pfaltz reported the first iridium N,P based catalyst capable of reducing 
1,1-disubstituted alkenes in useful selectivity (Ir–SerPHOX).
[18]
 The later developed catalyst 
Ir–ThrePHOX was found to give even higher enantioselectivities and is now commercially 
available as the BArF salt.
[19]
 First of all, the authors investigated aryl-alkyl substituted 
terminal alkenes with successful results in terms of conversion and enantiomeric excess (ee) 
(Figure 13). Later, they tested these catalysts with an allylic alcohol obtaining satisfactory 
results regarding conversion and ee. 
 
Figure 13 Substrates used by Pfaltz in the asymmetric hydrogenation. 
Andersson and Dieguez asymmetric hydrogenation of unfunctionalized olefins 
with biarylphosphinite-Ir-PHOX libraries 
A combined research effort by the groups of Dieguez, Andersson, and Borner initiated a 
combinatorial study utilizing the SerPHOX and ThrePHOX backbones in combination with a 
chiral biarylphosphinite moiety. A library of 96 possible phosphite oxazoline ligands was 
synthesized with systematic changes to the backbone and with special attention to the biaryl 
phosphite group (Figure 14).  
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Figure 14 Library of phosphite oxazoline ligands. 
This large class of complexes was found to be highly selective for the hydrogenation of aryl–
alkyl substituted terminal alkenes, terminal alkenes bearing two sterically different aryl 
groups, and heterocyclic substrates (Figure 15). 
 
Figure 15 Asymmetric hydrogenation with the phosphite oxazoline library.  
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Zhang asymmetric hydrogenation of allylic amines 
Zhang’s group published on 2005 the first work about catalytic asymmetric hydrogenation of 
di-substituted allyl phthalimides 
[32]
 mediated by Rh and Ru complexes, to form chiral 
phthalimides which act as precursors to the β-methyl chiral amines. The asymmetric 
hydrogenation reaction was carried out on a variety of substrates as we can see in Figure 16. 
 
Figure 16 Asymmetric hydrogenation of allyl phthalimides performed by Zhang. 
Substrates with a primary n-alkyl substituent such as ethyl, n-butyl, or benzyl group at the 2-
position of the allylphthalimides afforded products with high ee values. In contrast, the 
hydrogenation of the aromatic substrate proceeded with moderate enantioselectivity. 
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Aim of the thesis 
Chiral β-methyl amines 
β -chiral amines bearing a methyl group on the chiral center, and their derivatives, are key 
structural elements in natural products and pharmaceuticals.
[33,34] 
 
 
Figure 17 Examples of chiral β-methyl amines. 
For example, in  
Figure 17, compound A is a potent positive allosteric modulator of 2-amino-3-(5-methyl-3-
hydroxyisoxazol-4-yl)-propanoic acid (AMPA) receptors. 
[35]
 Compound B (NPS 1392) is a 
potent stereoselective antagonist of the NMDA receptor, which can be used for the control of 
ischemic strokes 
[36]
, whereas compound C (Lorcaserin) is the active principle of a 
commercial anorectic drug. 
[37]
 For these substrates, although several asymmetric syntheses 
based on kinetic resolution or stoichiometric reagents have been explored 
[38]
 there is not any 
literature reports in which asymmetric hydrogenation is employed as the key step of the 
reaction. It remains a significant challenge. 
Towards this task, our group has studied the catalytic asymmetric hydrogenation of N-tosyl 
allylic amines.
 [39]
 Although the reactions worked very well, the difficulties encountered in the 
removal of the N-tosyl protecting group was a significant shortcoming of this approach. To 
overcome this drawback, the focus was moved to the asymmetric hydrogenation of allylic 
phthalimides. The phthalimides are of great interest because they are easily synthesized 
compounds, and, in contrast with the previously applied N-tosyl products, much easier to 
deprotect under hydrazinolytic conditions. 
[32]
 As mentioned, the only examples available for 
the catalytic asymmetric hydrogenation of allylic phthalimides do not accommodate arylic 
substrates with good results. However, some very preliminary experiments collected in the 
group have shown that it should be possible to achieve good results in this reaction by using 
some iridium-P,N complexes. 
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On these premises, the aim of my thesis has been: 
1) Study, develop and optimize the catalytic asymmetric hydrogenation reaction of a 
representative phenyl allylic phthalimide substrate using different Ir-P,N complexes 
and reaction conditions. (Figure 18) 
 
 
Figure 18 Optimization of the asymmetric hydrogenation with the phenyl substrate. 
2) Study the scope of the reaction by synthesizing a series of phthalimide substrates and 
testing their behavior under the optimized conditions.(Figure 19) 
 
 
Figure 19 The scope of the asymmetric hydrogenation. 
3) Apply the catalytic methodology towards a synthetic target. Lorcaserin was identified 
as suitable target, based on the following retrosynthetic analysis. (Figure 20) 
 
 
Figure 20 The retrosynthesis of Lorcaserin. 
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Results and discussion 
Substrates 
The substrates for the asymmetric hydrogenation reactions were prepared via a three-step 
sequence from commercially available acetophenones. The first step is a Wittig olefination, as 
outlined in Figure 21, and afforded the desired olefins in good yields (>80%). The olefins 
were used directly in the second step (halogenation reaction) without further purification. 
 
Figure 21 The first step of the synthesis. 
The second step of the sequence is a halogenation in the alpha position of the terminal alkene, 
as shown in Figure 22. The reaction proceeds via radical mechanism and the halogenated 
product is obtained in good yields. During the synthesis of the ortho-bromophenyl substrate 
we realized that the halogenated product was quite lachrymatory. For this reason, for this 
substrate the reaction was conducted in a laboratory dedicated to dangerous compounds. The 
halogenated olefins were used directly in the third step (amination reaction) without further 
purification. 
 
Figure 22 The second step of the synthesis. 
The third and the last reaction is a simple SN2 (nucleophilic substitution reaction, Figure 23). 
The reaction afforded the products in good yields and quite clean; nevertheless, the products 
needed purification for the next step of the study (asymmetric hydrogenation). Thus, silica gel 
chromatography was performed using an automated chromatography system.  
 
Figure 23 The third step of the synthesis. 
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Catalysts screening  
Albert Cabré, the PhD student who has supervised me during the work of this thesis, has 
worked on the asymmetric hydrogenation, and, more in the specific, on the asymmetric 
hydrogenation of N-tosyl allyl amines.
[39]
 During his work, he also tried to hydrogenate 
different related substrates, with good results for conversion and enantiomeric excess. One of 
these substrates was an aryl N-allyl phathalimide. The hydrogenation of this substrate was 
performed asymmetrically using the UbaPHOX catalyst, which was designed by Pfaltz, and 
now is commercial available (Figure 24). The reaction gave the desired product with excellent 
yield and good ee, but the operative conditions were far from being optimal. 
 
Figure 24 Preliminary results in the asymmetric hydrogenation of phthalimides. 
Thus, with these promising results in hand, we decided to study the asymmetric 
hydrogenation of allylic phthalimides in detail, starting with the optimization of the reaction 
on the simple phenyl substrate (Table 1). For doing this, we decided to start with a screening 
of catalysts, carrying out the reaction with the operative conditions found by Albert Cabré, 
with slight modifications (Figure 25).  
 
Figure 25 Scheme of the reaction. 
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Thus, we decided to test different Iridium P,N catalysts including the MaxPHOX family 
which was introduced by our research group. Furthermore, a Rhodium catalyst was also tested 
to confirm the poor reactivity and enantiomeric induction with these types of substrates. 
 
Figure 26 The Rh complex and the commercial catalyst used in the catalyst screening. 
The structure is shown in Figure 26 and as above mentioned is a Rh complex in which the 
backbone belong to the MaxPHOS family. The second structure in Figure 26 is a Pfaltz’s 
catalyst which is commercially available. All the others belong to the Ir-MaxPHOX family, 
which were synthetized within the research group (Figure 27). 
Table 1 Catalysts screening of the asymmetric hydrogenation  
Entry
a 
Catalyst Cat. Loading Conversion
b
 (%)
 
ee
c
 (%) 
1 1 10 mol% 29 n.d. 
2 Ir-1 iPr 5 mol% >99 6 
3 Ir-2 iPr 5 mol% >99 64 
4 Ir-3 iPr 5 mol% >99 20 
5 Ir-4 iPr 5 mol% >99 32 
6 4 5 mol% 78 7 
7 Ir-2 tBu 5 mol% >99 90 
 a
Reaction conditions: substrate (0.2 mmol), DCM (2 mL), cat. (x mol%), 1 bar H2, RT, 17 h. 
b 
Determined by 
1
H 
NMR spectroscopy. 
c 
Determined by chiral stationary phase HPLC. 
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Figure 27 The MaxPHOX catalysts synthetized by our group. 
As expected, the asymmetric hydrogenation of this substrate works well with the Ir P,N 
catalysts in terms of conversion but the results are not satisfactory regarding the ees, while the 
rhodium and the commercial iridium catalysts 1 and 4 give poor results.(Table 1 entry 3) 
which allows obtaining the hydrogenated product with excellent yield and moderate values of 
enantiomeric excess. We decided to carry out another experiment to see if the chiral 
substituents which lie on the backbone of the Iridium catalyst could influence the 
enantioselectivity. Thus, since the catalyst which works better is the diastereoisomer 2, we 
thought to employ the same diastereoisomer but with a different substituent on the chiral 
oxazoline portion. In this case, instead of an isopropyl group, there is a ter-butyl group 
(Figure 28), which is more sterically hindered. 
 
Figure 28 The structure of the Ir(MaxPHOX)-2 t-Bu catalyst. 
As we can see from the Table 1(Entry 8) this catalyst can afford the hydrogenated product in 
excellent yield and with a good, yet not fully satisfactory, ee. After this result, we decided to 
investigate how the catalyst and, more generally, the reaction performs under high pressure. 
Accordingly, we carried out the asymmetric hydrogenation as shown in Figure 29, with the 
catalysts which gave the best results: Ir-2 iPr and Ir-2 tBu. 
In Table 2 we can see that both catalysts manage to catalyze the reaction by providing a full 
conversion; nevertheless the enantiomeric excess has worsened respect the previous reaction 
with lower hydrogen pressure. In particular, we can see the Ir-2 iPr loses several percentage 
points of ee (56% vs 64%) whereas the Ir-2 tBu has lowered his ee by a few percentage points 
(88% vs 90%). 
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Figure 29 Scheme of the reaction with high pressure. 
Table 2 Catalysts screening changing the pressure 
Entry
a 
Catalyst Cat. Loading (mol %) Conversion (%)
b 
ee (%)
c 
1 Ir-2 iPr 5 >99 56 
2 Ir-2 tBu 5 >99 88 
a
Reaction conditions: substrate (0.2 mmol), DCM (2 mL), cat. (5 mol%),50 bar H2, RT, 17 h.  
b 
Determined by 
1
H NMR spectroscopy. 
c 
Determined by chiral stationary phase HPLC. 
After this preliminary investigation, we can conclude that the best catalyst for giving high 
conversion and good ee is the Ir-2-t-Bu. This is a good result, because the catalyst has been 
designed within the research group, giving an added value to my work.
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Optimization of reaction conditions 
For the optimization of the reaction, we changed some operative conditions to see how the 
reaction responded (Figure 30).  
 
Figure 30 Scheme of the reaction. 
We started trying to reduce the catalyst loading. Normally, for asymmetric synthesis, it is 
important to minimize as much as possible the quantity of catalyst in the reaction to reduce its 
cost for a possible future industrial application.  
As can be seen from the Table 3, we have reduced the catalytic load from 5 mol % to 1 mol % 
(Entries 1,2). The reaction goes to full conversion and the ee is not affected at all. 
Subsequently, we have moved our attention to the screening of the solvents. We tried solvents 
more coordinating than dichloromethane, such as EtOAc and THF. As we expected (see 
Introduction) the results in terms of conversion and ee are worse, as shown in the Table 3, 
Entries 3,4. 
As last change in operative conditions, we have done an experiment changing the 
temperature. As displayed in the Table 3 we have lowered the temperature up to -20 °C using 
a cryo-cool machine.  
Table 3 The optimization of the reaction: screening of catalyst load, solvent and temperature 
Entry
a 
Cat. load (mol %) Solvent Temperature (°C) Conversion (%)
b 
Ee (%)
c 
1 5 DCM Rt >99 90 
2 1 DCM Rt >99 90 
3 1 EtOAc Rt 60 89 
4 1 THF Rt 5 n.d. 
5 1 DCM -20 >99 98 
a
Reaction conditions: substrate (0.2 mmol), Solvent (2 mL), Ir(MaxPHOX)-2 t-Bu (x mol%), 1 bar H2, 
Temperature, 17 h. 
b 
Determined by 
1
H NMR spectroscopy. 
c 
Determined by chiral stationary phase HPLC. 
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It is quite common in asymmetric synthesis to reduce the temperature to favor the formation 
of one of the two possible enantiomers. In fact, lowering the temperature we could see an 
increase of enantiomeric excess, and up to 98% of ee was afforded (Entry 5). 
Finally, we can state that the best operating conditions for this reaction are: 1 mol % of 
catalytic loading, in DCM, 1 bar pressure, -20°C (Figure 31). 
 
Figure 31 Optimized conditions for the asymmetric hydrogenation. 
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Scope of the asymmetric hydrogenation reaction  
After all the screenings for finding the best conditions for the asymmetric hydrogenation we 
investigated the scope of the reaction, using the previously synthetized substrates changing 
the substituents in the aromatic ring of the terminal alkene, with both electron withdrawing 
group and electron donor group in ortho-, meta- and para-position. 
The operating conditions are those previously studied and found to be the best, and are shown 
in Figure 32. 
 
Figure 32 Asymmetric hydrogenation of different phthalimide substrates. 
In Table 4 are displayed the results of the hydrogenation of all the substrates. We can say that 
the Ir P,N catalyst can promote the formation of the hydrogenated product with excellent 
enantioselectivity, irrespective of the nature and position of the substituent on the aromatic 
ring. In fact, we can say that our catalyst induces excellent ee’s for the para- and meta- 
positions with ee’s up to 99%, whereas, for the ortho-position the ee’s are lower but still good 
with values up to 91% of ee. We can induce excellent enantioselectivity also with napthalenic 
substituents.  
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Table 4 The scope of the asymmetric hydrogenation  
Substrate (R) Conversion
a 
(%) Ee
b 
(%) 
H (standard substrate) >99 98 
p-Me >99 97 
p-F
 
>99 >99 
p-Cl
 
97 97 
p-I
 
99 98 
p-Br 99 97 
m-MeO >99 98 
m-Cl >99 99 
o-Me >99 91 
o-Br >99 90 
o-MeO 98 83 
2-Naph
 
>99 97 
a
Determined by 
1
H NMR spectroscopy. 
b
Determined by chiral stationary phase HPLC. 
After an experiment of hydrogenation of the para-fluorine substrate we noted in the NMR 
spectrum some other signals which did not belong to the hydrogenated product. In fact, we 
noted near the characteristic signals of the double bound of the terminal alkene of the starting 
substrate two small signals. Initially, we did not understand what it was. Thus, we carried out 
an experiment at reduced reaction times. Without further purification we brought the reaction 
crude directly to 
1
H-NMR analysis. The spectrum is shown below in Figure 33. 
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Figure 33 The isomerization of the substrate with an electron withdrawing group. 
Examining the NMR spectrum we noted that the more intense signals derived from the double 
bound of our starting material accompanied by the two, previously detected, signals of the 
new product which was now identified as the E and Z form of an enamide derived by 
isomerization of the starting substrate. Therefore, we supposed that when there is an electron-
withdrawing group on the aromatic ring, such as the fluorine, our substrate could isomerize.  
This isomerization could be a problem in the HPLC analysis. Thus after this discovery, we 
have purified all the substrates with EWG in the aromatic ring, leading to the results reported 
in Table 4. 
In conclusion, we have been able to isolate and characterize the hydrogenated products with 
excellent results in terms of conversion, and especially, enantiomeric excess. 
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Synthetic application 
By the high importance of chiral β-methyl amines in the biological field, we were encouraged 
to prove the applicability of our catalytic methodology. We set our efforts on the synthesis of 
(R)-Lorcaserin. It presents a tetrahydro-3-benzazepine skeleton, which is a common structural 
feature in many natural and pharmaceutical products. Lorcaserin has serotonergic properties 
and is currently used as a weight-loss drug. 
[35,37] 
Several racemic synthesis of this compound 
have been reported. In its asymmetric form, only few strategies can be found in the literature, 
most of them using kinetic resolution or stoichiometric reagents, and even less applying 
asymmetric catalysis.
[37]
 For this reason, we envisioned that we could apply the novel 
synthetic methodology presented here to develop a new access to lorcaserin in enantiopure 
form. 
For this purpose, the corresponding meta-chlorophenyl acetophenone was used as starting 
material for a 8-step synthetic route to afford optically pure (R)-Lorcaserin (Figure 34). After 
the synthesis of our phthalimide, the corresponding selective Ir-catalyzed asymmetric 
hydrogenation took place smoothly, to afford the hydrogenated product in good yield and 
with excellent ee. Further deprotection gave the corresponding free amine in 65% yield. 
[32]
  
 
Figure 34 The synthetic pathway proposed. 
This amine has been already used in the literature as the key starting material for the synthesis 
of Lorcaserin through an N-acylation followed by reduction. 
[40]
 As last step of the synthesis, 
a Lewis-acid promoted intramolecular Friedel-Crafts alkylation was used. This reaction 
occurred selectively to the para-position of the aromatic ring due to steric control, thus 
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forming a 7-membered ring and, consequently, Lorcaserin. In conclusion, we proposed this 
synthetic pathway which includes our asymmetric hydrogenation as the key step of the 
synthesis.  
27 
 
Conclusions  
Considering the results obtained, we were able to achieve our goals. In particular, we can 
conclude that: 
1. we have found satisfactory conditions for our planned asymmetric hydrogenation 
using a non-commercial catalyst developed by our research group (Figure 35) 
 
Figure 35 The optimized reaction. 
2. We studied the reaction with several different substrates, and we obtained good results 
in terms of yields and, enantiomeric excesses independently from the aromatic 
substituent. (Figure 36) 
 
Figure 36 The scope of the reaction. 
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3. A synthetic application of our optimized reaction was shown, by the formal synthesis 
of Lorcaserin. (Figure 37) 
 
Figure 37 The total formal synthesis of Lorcaserin. 
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Experimental Part 
General information 
General procedures and materials 
Unless otherwise indicated, materials were obtained from commercial suppliers and used 
without further purification. All reactions that required anhydrous conditions were performed 
in dried glassware under a dry nitrogen atmosphere. Dichloromethane and THF were 
degassed and anhydrised with a solvent purification system (SPS PS-MD-3). Anhydrous 
dichloroethane and DMF were used from Sigma Aldrich. Solvents were removed under 
reduced pressure with a rotary evaporator. Silica gel chromatography was performed using an 
automated chromatography system (PuriFlash® 430, Interchim). 
Instrumentation 
NMR spectroscopy: 
1
H and 
13
C were recorded on the NMR spectrometers of the Centres 
Científics i Tecnològics de la Universitat de Barcelona. The employed spectrometers were a 
Varian Mercury 400 MHz. Chemical shifts (δ) were referenced to internal solvent resonances 
and reported relative to TMS (tetramethylsilane). The coupling constants (J) are reported in 
Hertz (Hz). The following abbreviations are used to define multiplicities: s (singlet), d 
(doublet), t (triplet), q (quartet), dd (doublet of doublets), ddd (doublet of doublet of 
doublets), ddd (doublet of doublet of triplets), dddd (doublet of doublet of doublet of 
doublets), dt (doublet of triplets), td (triplet of doublets), ddq (doublet of doublet of quartets),  
dtd (doublet of triplet of doublets), dq (doublet of quartets), tt (triplet of triplets), qt (quartet of 
triplets), m (multiplet), br s (broad signal).  
High Resolution Mass Spectrometry: High resolution ESI-MS spectra were recorded in an 
LC/MSD-TOF G1969A (Agilent Technologies) of the Centres Científics i Tecnològics de la 
Universitat de Barcelona. 
 
IR spectroscopy: IR spectra were measured in a Thermo Nicolet 6700 FT-IR spectrometer 
using an ATR system, of the Department of Organic Chemistry in the Universitat de 
Barcelona. 
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Optical rotations were measured at room temperature (25°C) using a Jasco P-2000 iRM- 800 
polarimeter. Concentration is expressed in g/100 mL. The cell sized 10 cm long and had 1 mL 
of capacity, measuring λ was 589 nm, which corresponds to a sodium lamp.  
Melting points were determined using a Büchi melting point apparatus and were not 
corrected. 
Experimental procedure for the synthesis of catalyst Ir-MaxPHOS t-Bu 2 
Following the experimental procedure described in the literature 
[41]
, catalysts were afforded 
after 4 synthetic steps.  
            
(R)-2-amino-N-((R)-1-hydroxy-3,3-dimethylbutan-2-yl)-3-methylbutanamide, S1 
 
Following the experimental procedure described in the literature 
[41]
, S1 was obtained as a white solid (5.52 g, 
89% yield). m.p. 87 - 91 ºC. [α]D
25
: +36 (c 0.7, CHCl3).  
1
H NMR (CDCl3, 400 MHz) δ: 7.80 (d, J = 8.4 Hz, 
1H), 3.90 (ddd, J = 11.0, 3.1, 0.6 Hz, 1H), 3.76 (td, J = 8.6, 3.1 Hz, 1H), 3.54 (ddd, J = 11.0, 8.6, 0.6 Hz, 1H), 
3.33 (d, J = 3.6 Hz, 1H), 2.42 – 2.31 (m, 1H), 1.99 (s, 2H), 1.02 (d, J = 7.0 Hz, 3H), 0.97 (s, 9H), 0.83 (d, J = 6.9 
Hz, 3H) ppm. 
13
C NMR (101 MHz, CDCl3) δ: 176.26, 64.26, 60.26, 33.21, 30.58, 27.14, 19.97, 16.11 ppm. 
HRMS (ESI) calculated for C11H25N2O2 217.1911, found 217.1917 [M+H]
+
. IR (ATR-FTIR) νmax = 3324, 3292, 
2953, 2869, 1650, 1629, 1537 cm
-1
. 
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(R)-2-(((S)-tert-butyl(methyl)phosphanyl)amino)-N-((R)-1-hydroxy-3,3-dimethylbutan-2-yl)-3-
methylbutanamide borane, S2 
 
Following the experimental procedure described in the literature 
[41]
, S2 was obtained as a white solid (2.06 g, 
69% yield). m.p. 150-152 ºC. [α]D
25
: +27 (c 0.8, CHCl3).  
1
H NMR (400 MHz, CDCl3) δ 6.07 (d, J = 8.8 Hz, 
1H), 3.87 (dd, J = 11.2, 3.1 Hz, 1H), 3.79 (ddd, J = 8.9, 7.7, 3.1 Hz, 1H), 3.58 (dd, J = 11.2, 7.7 Hz, 2H), 2.15 (s, 
1H), 2.12 – 2.05 (m, 1H), 1.36 (d, J = 8.9 Hz, 3H), 1.14 (d, J = 14.1 Hz, 9H), 1.00 (d, J = 6.8 Hz, 3H), 0.97 (s, 
9H), 0.93 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 174.46, 110.21, 63.65, 62.83, 60.44, 33.31, 32.77, 
32.74, 31.08, 30.69, 27.19, 24.73, 24.70, 19.72, 17.95, 10.68, 10.29. 31P NMR (202 MHz, CDCl3) δ 71.0 – 71.0 
(m, P-BH3) ppm. HRMS (ESI) calculated for C16H39BN2O2P 333.2842, found 333.2849 [M+H]
+
. IR (ATR-
FTIR) νmax = 3312, 3244, 2960, 2861, 2367, 2328, 1644, 1556, 1366, 1067, 1052 cm
-1
. 
 
 
(S)-1-tert-butyl-N-((R)-1-((R)-4-(tert-butyl)-4,5-dihydrooxazol-2-yl)-2-methylpropyl)-1-
methylphosphanamine borane, S3 
 
 
Following the experimental procedure described in the literature
[41]
, S3 was obtained as an oil (1.02 g, 80% 
yield). [α]D
25
: +28 (c 0.6, CHCl3).  
1
H NMR (CDCl3, 400 MHz) δ 4.22 (dd, J = 10.2, 8.7 Hz, 1H), 4.06 (t, J = 8.6 
Hz, 1H), 3.95 (dt, J = 10.0, 5.0 Hz, 1H), 3.84 (ddd, J = 10.2, 8.5, 0.7 Hz, 1H), 2.35 (d, J = 10.0 Hz, 1H), 2.00 
(dtd, J = 13.8, 6.9, 4.6 Hz, 1H), 1.33 (d, J = 9.0 Hz, 3H), 1.14 (d, J = 14.0 Hz, 9H), 0.94 (d, J = 6.8 Hz, 3H), 0.90 
(s, 9H), 0.89 (d, J = 6.9 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 75.49, 69.13, 56.74 (d, J = 2.6 Hz), 33.62 (d, J 
= 2.9 Hz), 33.52, 31.31 (d, J = 37.8 Hz), 25.98, 24.63 (d, J = 3.2 Hz), 18.60, 17.70, 10.65 (d, J = 42.2 Hz). 31P 
NMR (202 MHz, CDCl3) δ 70.5 – 69.5 (m, P-BH3) ppm. HRMS (ESI) calculated for C16H37BN2OP 315.2731, 
found 315.2742 [M+H]
+
. IR (ATR-FTIR) νmax = 3332, 2958, 2865, 2390, 2368, 2336, 1668, 1464, 1357, 1137 
cm
-1
. 
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[Ir(MaxPHOS)(COD)]BArF, t-Bu 2
 
 
Following the experimental procedure described in the literature
[41]
,Ir-MaxPHOS t-Bu 2 was obtained as an 
orange solid (162 mg, 70% yield). m. p. 228 - 230 ºC (descomposition). [α]D
25
: -76 (c 0.3, CHCl3). 
1
H NMR 
(CDCl3, 400 MHz) δ 7.71 (s, 5H), 7.53 (s, 4H), 4.87 (s, 1H), 4.59 (dd, J = 9.7, 3.4 Hz, 2H), 4.44 (p, J = 7.3 Hz, 
1H), 4.25 (t, J = 9.7 Hz, 1H), 3.92 (dd, J = 9.1, 3.4 Hz, 2H), 3.28 (ddd, J = 25.2, 9.3, 7.0 Hz, 1H), 2.46 (dd, J = 
15.6, 7.9 Hz, 1H), 2.40 – 2.17 (m, 4H), 2.16 – 2.04 (m, 2H), 1.91 (dt, J = 13.9, 9.0 Hz, 1H), 1.57 (d, J = 6.3 Hz, 
3H), 1.52 – 1.42 (m, 2H), 1.17 – 1.06 (m, 12H), 1.00 (s, 9H), 0.88 (d, J = 6.7 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 175.32, 162.59, 162.09, 161.59, 161.10, 134.94, 129.51, 129.45, 129.20, 129.17, 128.88, 128.83, 
128.59, 128.55, 126.05, 123.35, 117.66, 117.63, 117.59, 117.55, 93.06, 92.96, 88.24, 88.10, 72.38, 71.10, 63.41, 
59.25, 56.32, 38.85, 38.82, 37.79, 37.74, 36.09, 35.71, 34.17, 33.32, 33.30, 28.91, 25.92, 25.88, 25.42, 24.40, 
24.38, 21.45, 18.37, 16.51, 16.22. 31P NMR (202 MHz, CDCl3) δ 53.8 ppm. HRMS (ESI) calculated for 
C24H45N2OPIr 601.2893, found 601.2914 [M+H]
+
. IR (ATR-FTIR) νmax = 3430, 2961, 1624, 1612, 1352, 1273, 
1157, 1119, 1094 cm
-1
. 
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Experimental procedures and characterization data 
 
Preparation of the aryl-substituted N-allyl phthalimides 
 
Step 1. In an oven dried flask, methyl triphenylphosphonium bromide (1.2 equiv.) was taken 
and to this anhydrous THF (1.6 mL/mmol) was added. The suspension was cooled to 0 ºC, 
KOtBu (1.2 equiv.) was added and the resulting yellow suspension was stirred at 0 ºC for 45 
min. To this suspension, a solution of ketone (1.0 equiv.) in THF (0.7 mL/mmol) was added 
dropwise and the resulting mixture was warmed gradually to r.t. and stirred at r.t. for 16 
hours. Afterwards, the reaction mixture was concentrated and redissolved with hexanes. The 
crude was filtered by a plug of silica and washed (x3) with hexanes, to afford the desired 
product which was used for the next step without further purification.  
Step 2. In an oven dried flask the alkene (1 equiv.) was dissolved in THF (3 mL/mmol). To 
the resulting solution, NBS (1.05 equiv.) and p-TsOH (0.1 equiv.) were added and the 
solution was refluxed for 4 hours at 100ºC. Afterwards, the reaction mixture was cooled to 
room temperature and taken up with Hexane (15 mL/mmol), washed three times with H2O 
(15 mL x 3) and the organic layer dried over MgSO4. The solvent was removed in vacuum 
and an oil was obtained which was used for the next step without further purification.
[42]
 
Step 3. Potassium phthalimide (1.1 equiv.) was added to a solution of the α-bromo alkene (1 
equiv.) in DMF (2.76 mL/mmol) at room temperature. The resulting mixture was stirred for 
18 hours. Afterwards, DCM (30 mL) was added and the mixture poured onto water (100 mL). 
The aqueous phase was separated and extracted with DCM for three times. The combined 
organic extract was then washed with NaOH aq. (0,2 M) and dried over MgSO4. The solvent 
was removed in vacuum and the residue purified by column chromatography (Hexane:EtOAc 
70:30) to afford the protected product as white solid.
 [43
 
For the synthesis of the following compounds, 1 g of ketone was used as starting material for 
all cases.  
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2-(2-phenylallyl)isoindoline-1,3-dione 
 
White solid (790 mg, 50% yield). 1H NMR (400 MHz, CDCl3) δ 7.85 (dd, J = 5.4, 3.1 Hz, 2H), 7.71 (dd, J = 
5.5, 3.0 Hz, 2H), 7.52 – 7.48 (m, 2H), 7.37 – 7.28 (m, 2H), 5.44 (t, J = 0.9 Hz, 1H), 5.16 (t, J = 1.6 Hz, 1H), 4.71 
(t, J = 1.3 Hz, 2H). The analytical data for this compound were in excellent agreement with the reported data.
[44]
 
 
2-(2-(4-fluorophenyl)allyl)isoindoline-1,3-dione 
 
White solid (696 mg, 34% yield). 1H NMR (400 MHz, CDCl3) δ 7.84 (dd, J = 5.5, 3.0 Hz, 2H), 7.74 – 7.69 (m, 
2H), 7.49 – 7.43 (m, 2H), 7.05 – 6.98 (m, 2H), 5.39 (s, 1H), 5.19 – 5.16 (m, 1H), 4.67 (t, J = 1.3 Hz, 2H). The 
analytical data for this compound were in excellent agreement with the reported data.
[43]
 
 
2-(2-(4-chlorophenyl)allyl)isoindoline-1,3-dione 
 
White solid (845 mg, 44% yield). 1H NMR (400 MHz, CDCl3) δ 7.87 – 7.81 (m, 2H), 7.75 – 7.69 (m, 2H), 7.45 
– 7.40 (m, 2H), 7.33 – 7.27 (m, 2H), 5.44 – 5.42 (m, 1H), 5.22 (t, J = 1.6 Hz, 1H), 4.67 (dd, J = 1.5, 1.0 Hz, 2H). 
The analytical data for this compound were in excellent agreement with the reported data.
[43] 
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2-(2-(4-bromophenyl)allyl)isoindoline-1,3-dione 
 
White solid (608 mg, 35% yield). 1H NMR (400 MHz, CDCl3) δ 7.84 (dd, J = 5.4, 3.1 Hz, 2H), 7.71 (dd, J = 
5.5, 3.0 Hz, 2H), 7.48 – 7.43 (m, 2H), 7.39 – 7.35 (m, 2H), 5.44 (d, J = 1.1 Hz, 1H), 5.23 (t, J = 1.5 Hz, 1H), 
4.67 (dd, J = 1.5, 1.0 Hz, 2H). The analytical data for this compound were in excellent agreement with the 
reported data.
[45]
 
 
2-(2-(4-iodophenyl)allyl)isoindoline-1,3-dione 
 
White solid (620 mg, 39% yield). m.p. 178-181ºC. 1H NMR (400 MHz, CDCl3)
 
δ 7.87 – 7.79 (m, 2H), 7.74 – 
7.68 (m, 2H), 7.65 (dq, J = 8.1, 1.6, 1.2 Hz, 2H), 7.25 – 7.21 (m, 2H), 5.44 (s, 1H), 5.22 (d, J = 1.6 Hz, 1H), 4.66 
(p, J = 0.8 Hz, 2H).
 13
C NMR (101 MHz, CDCl3)
 
δ 168.05, 141.79, 138.09, 137.66, 134.23, 132.08, 128.44, 
123.57, 115.23, 93.96, 41.39. HRMS (ESI) calculated for C17H12INO2 389.9985, found 389.9988 [M+H]
+
. IR 
(ATR-FTIR) νmax = 1766, 1703, 1390, 1110 cm
-1
. 
 
2-(2-(p-tolyl)allyl)isoindoline-1,3-dione 
 
White solid (679 mg, 33% yield). 1H NMR (400 MHz, CDCl3) δ 7.86 – 7.82 (m, 2H), 7.71 (dd, J = 5.5, 3.1 Hz, 
2H), 7.42 – 7.38 (m, 2H), 7.17 – 7.11 (m, 2H), 5.41 (d, J = 1.4 Hz, 1H), 5.14 – 5.07 (m, 1H), 4.69 (t, J = 1.4 Hz, 
2H), 2.33 (s, 3H). The analytical data for this compound were in excellent agreement with the reported data.
[43]
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2-(2-(3-chlorophenyl)allyl)isoindoline-1,3-dione 
 
White solid (584 mg, 30% yield). m.p. 122-124 ºC. 1H NMR (400 MHz, CDCl3) δ 7.85 – 7.77 (m, 2H), 7.70 – 
7.64 (m, 2H), 7.45 (dt, J = 2.5, 1.0 Hz, 1H), 7.35 (ddd, J = 6.3, 2.8, 1.7 Hz, 1H), 7.26 – 7.21 (m, 2H), 5.42 (d, J = 
1.1 Hz, 1H), 5.18 (t, J = 1.6 Hz, 1H), 4.64 (t, J = 1.4 Hz, 2H). 
13
C NMR (101 MHz, CDCl3) δ 167.83, 141.34, 
140.32, 134.35, 134.07, 131.92, 129.63, 128.09, 126.69, 124.49, 123.41, 115.18, 41.20. HRMS (ESI) calculated 
for C17H12ClNO2 298.0629, found 298.0631 [M+H]
+
. IR (ATR-FTIR) νmax = 3029, 2927, 1775, 1709, 1390   cm
-
1
. 
 
2-(2-(3-methoxyphenyl)allyl)isoindoline-1,3-dione 
  
White solid (834mg, 43% yield). 1H NMR (400 MHz, CDCl3) δ 7.84 (dd, J = 5.5, 3.0 Hz, 2H), 7.71 (dd, J = 5.4, 
3.0 Hz, 2H), 7.25 – 7.22 (m, 1H), 7.09 (ddd, J = 7.7, 1.7, 1.0 Hz, 1H), 7.06 – 7.02 (m, 1H), 6.83 (ddd, J = 8.2, 
2.6, 0.9 Hz, 1H), 5.45 (q, J = 1.0 Hz, 1H), 5.17 (t, J = 1.6 Hz, 1H), 4.69 (t, J = 1.3 Hz, 2H), 3.82 (s, 3H). 
The analytical data for this compound were in excellent agreement with the reported data.
[44]    
2-(2-(2-bromophenyl)allyl)isoindoline-1,3-dione 
 
White solid (635 mg, 37% yield). m.p. 120-122 ºC. 1H NMR (400 MHz, CDCl3) δ 7.86 – 7.80 (m, 2H), 7.74 – 
7.68 (m, 2H), 7.58 – 7.54 (m, 1H), 7.25 – 7.18 (m, 2H), 7.13 (ddd, J = 7.9, 6.8, 2.3 Hz, 1H), 5.38 (td, J = 1.5, 0.7 
Hz, 1H), 5.16 (q, J = 1.0 Hz, 1H), 4.62 (t, J = 1.3 Hz, 2H)..
 13
C NMR (101 MHz, CDCl3)
 
δ 167.70, 143.48, 
140.78, 133.96, 132.73, 131.98, 130.59, 129.20, 127.22, 123.32, 122.30, 117.34, 42.37. HRMS (ESI) calculated 
for C17H12BrNO2 342.0124, found 342.0126 [M+H]
+
. IR (ATR-FTIR) νmax = 3069, 2914, 1770, 1705, 1421, 
1389, 1108 cm
-1
. 
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2-(2-(2-methoxyphenyl)allyl)isoindoline-1,3-dione 
 
White solid (479 mg, 25% yield). 1H NMR (400 MHz, CDCl3) δ 7.81 (ddd, J = 5.5, 3.2, 0.4 Hz, 2H), 7.69 (ddd, 
J = 5.7, 2.9, 0.4 Hz, 2H), 7.26 – 7.21 (m, 1H), 7.15 (dd, J = 7.6, 1.8 Hz, 1H), 6.89 – 6.83 (m, 2H), 5.26 – 5.21 
(m, 1H), 5.19 (dt, J = 1.3, 0.7 Hz, 1H), 4.71 (t, J = 1.3 Hz, 2H), 3.86 (s, 3H). The analytical data for this 
compound were in excellent agreement with the reported data.
[46]
 
 
2-(2-(o-tolyl)allyl)isoindoline-1,3-dione 
 
White solid (579 mg, 28% yield). m.p. 102-105 ºC. 1H NMR (400 MHz, CDCl3) δ 7.85 (dd, J = 5.4, 3.0 Hz, 
2H), 7.72 (dd, J = 5.4, 3.0 Hz, 2H), 7.22 – 7.08 (m, 4H), 5.19 (td, J = 1.8, 0.9 Hz, 1H), 5.03 (q, J = 1.4 Hz, 1H), 
4.49 (t, J = 1.6 Hz, 2H), 2.40 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 167.83 , 143.50 , 135.60 , 133.99 , 131.99 , 
130.17 , 128.69 , 127.63 , 125.53 , 123.34 , 114.32 , 42.82 , 19.58. HRMS (ESI) calculated for C18H15NO2 
278.1176, found 278.1175 [M+H]
+
. IR (ATR-FTIR) νmax = 3461, 3018, 2926, 2850, 1770, 1709, 1415, 1388, 
1113 cm
-1
. 
 
2-(2-(naphthalen-2-yl)allyl)isoindoline-1,3-dione 
 
White solid (713 mg, 39% yield). m.p. 165-168 ºC. 1H NMR (400 MHz, CDCl3) δ 7.96 (s, 1H), 7.84 (ddd, J = 
5.5, 3.1, 0.4 Hz, 2H), 7.82 – 7.78 (m, 2H), 7.72 – 7.68 (m, 2H), 7.64 (dd, J = 8.6, 1.9 Hz, 1H), 7.49 – 7.43 (m, 
2H), 5.59 (s, 1H), 5.29 (t, J = 1.5 Hz, 1H), 4.83 (t, J = 1.4 Hz, 2H).
 13
C NMR (101 MHz, CDCl3) δ 167.99, 
142.25, 135.67, 133.98, 133.20, 133.01, 131.99, 128.30, 127.99, 127.51, 126.22, 126.12, 125.26, 124.57, 123.35, 
114.59, 41.51. . HRMS (ESI) calculated for C21H15NO2 314.1176, found 314.1171 [M+H]
+
. IR (ATR-FTIR) 
νmax = 3092, 3056, 3021, 2923, 1770, 1698, 1425, 1397, 1108 cm
-1
. 
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Iridium-Catalyzed Asymmetric Hydrogenation of N-Allyl Phthalimides 
General procedure GP 
Into a low pressure reactor equipped with PTFE-coated stir-bar, the corresponding substrate 
(0.288 mmol, 1.0 equiv.) was charged and dissolved in anhydrous DCM (1 mL/0.1 mmol 
substrate). Once sealed, the reactor was purged and charged with 1 bar of H2. Then, the 
pressure reactor was placed in a cryocool bath. When it reached -20 ºC, the corresponding 
catalyst (t-Bu2) dissolved in 0.2 mL of anhydrous DCM was then added (1 mol%, otherwise 
indicated) with a pressure-syringe. The reaction was left stirring at -20 ºC overnight. 
Afterwards, the crude was filtrated with a short plug of silica to afford the corresponding 
isolated product. The conversion was measured by 
1
H NMR spectroscopy and the 
enantiomeric excess using chiral HPLC chromatography. 
 
(R)-2-(2-phenylpropyl)isoindoline-1,3-dione 
  
Following GP, the desired product was obtained as an oil (full conversion, 98% ee). 
1
H NMR (400 MHz, 
CDCl3) δ 7.75 – 7.69 (m, 2H), 7.64 – 7.58 (m, 2H), 7.21 – 7.18 (m, 4H), 7.15 – 7.09 (m, 1H), 3.83 – 3.68 (m, 
2H), 3.32 – 3.22 (m, 1H), 1.23 (d, J = 7.0 Hz, 3H). HPLC: CHIRALPAK IA. Heptane/iPrOH 90:10, 0.5 
mL/min, λ = 254 nm. t(R) = 12.5 min, t(S) = 14.3 min. The analytical data for this compound were in excellent 
agreement with the reported data.
[46] 
 
 
 
39 
 
 (R)-2-(2-(4-fluorophenyl)propyl)isoindoline-1,3-dione 
 
Following GP, the desired product was obtained as a white solid (full conversion, >99% ee). m.p. 60-63 ºC [α]D: 
+91.5 (c 1.2, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.82 – 7.76 (m, 2H), 7.72 – 7.66 (m, 2H), 7.24 – 7.18 (m, 
2H), 6.98 – 6.90 (m, 2H), 3.87 – 3.71 (m, 2H), 3.34 (h, J = 7.3 Hz, 1H), 1.29 (d, J = 7.0 Hz, 3H). 
13
C NMR (101 
MHz, CDCl3) δ 168.22, 162.86, 160.43, 138.89, 138.86, 133.90, 131.80, 128.74, 128.66, 123.20, 115.34, 115.13, 
44.85, 44.84, 37.81, 19.12.  HRMS (ESI) calculated for C17H14FNO2 284.1081, found 284.1081 [M+H]
+
. IR 
(ATR-FTIR) νmax = 2970, 2926, 2853, 2359, 2334, 2249, 1706, 1509, 1395, 1378, 1352, 1223 cm
-1
. HPLC: 
CHIRALPAK IA. Heptane/EtOH 50:50, 0.5 mL/min, λ = 210 nm. t(R) = 10.9 min, t(S) = 15.4 min. 
 
 
 
(R)-2-(2-(4-chlorophenyl)propyl)isoindoline-1,3-dione 
 
Following GP, the desired product was obtained as a a white solid (full conversion, 97% ee). m.p. 69-73 ºC [α]D: 
+98.8 (c 1.1, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.75 – 7.69 (m, 2H), 7.64 – 7.58 (m, 2H), 7.19 – 7.07 (m, 
4H), 3. 81 – 3.63 (m, 2H), 3.26 (h, J = 7.3 Hz, 1H), 1.21 (d, J = 7.0 Hz, 3H). 
 13
C NMR (101 MHz, CDCl3) δ 
168.21, 141.71, 133.92, 132.41, 131.79, 128.65, 128.59, 123.24, 77.31, 76.99, 76.68, 44.62, 37.98, 19.05. 
HRMS (ESI) calculated for C17H14ClNO2 300.0786, found 300.0797 [M+H]
+
. IR (ATR-FTIR) νmax 2970, 2926, 
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2853, 2363, 2242, 1767, 1708, 1394, 1378, 1351 cm
-1
. HPLC: CHIRALPAK IA. Heptane/EtOH 50:50, 0.5 
mL/min, λ = 210 nm. t(R) = 12.0 min, t(S) = 17.1 min. 
 
 
 
(R)-2-(2-(4-bromophenyl)propyl)isoindoline-1,3-dione 
 
Following GP and using 2 mol% of catalyst, the desired product was obtained as a white solid (full conversion, 
97% ee). m.p. 118-121 ºC [α]D: +98.4 (c 0.5, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.86 – 7.75 (m, 2H), 7.73 – 
7.65 (m, 2H), 7.42 – 7.33 (m, 2H), 7.17 – 7.09 (m, 2H), 3.88 – 3.69 (m, 2H), 3.33 (h, J = 7.3 Hz, 1H), 1.27 (d, J 
= 7.0 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 168.20, 142.24, 133.93, 131.78, 131.54, 129.04, 123.24, 120.51, 
44.52, 38.04, 19.02. HRMS (ESI) calculated for C17H14BrNO2 344.0281, found 344.0279 [M+H]
+
. IR (ATR-
FTIR) νmax = 2967, 2936, 2843, 2255, 1757, 1708, 1395, 1378, 1352 cm
-1
. HPLC: CHIRALPAK IA. 
Heptane/EtOH 50:50, 0.5 mL/min, λ = 210 nm. t(R) = 12.9 min, t(S) = 21.8 min. 
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(R)-2-(2-(4-iodophenyl)propyl)isoindoline-1,3-dione 
 
Following GP and using 2 mol% of catalyst, the desired product was obtained as a white solid (full conversion, 
98% ee). m.p. 151-155 ºC [α]D: +90.2 (c 0.5, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.84 – 7.76 (m, 2H), 7.73 – 
7.66 (m, 2H), 7.62 – 7.56 (m, 2H), 7.05 – 6.98 (m, 2H), 3.88 – 3.71 (m, 2H), 3.31 (h, J = 7.3 Hz, 1H), 1.27 (d, J 
= 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 168.21, 142.95, 137.52, 133.94, 131.79, 129.36, 123.25, 92.01, 
44.48, 38.14, 19.00. HRMS (ESI) calculated for C17H14INO2 392.0142, found 392.0142 [M+H]
+
. IR (ATR-
FTIR) νmax = 2963, 2927, 2366, 1770, 1697, 1391, 1036, 1004 cm
-1
. HPLC: CHIRALPAK IA. Heptane/IPA 
95:5, 0.5 mL/min, λ = 210 nm. t(R) = 11.1 min, t(S) = 13.0 min. 
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(R)-2-(2-(p-tolyl)propyl)isoindoline-1,3-dione 
 
Following GP, the desired product was obtained as a colorless solid (full conversion, 97% ee). m.p. 50-53 ºC 
[α]D: +93.7 (c 1.3, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.83 – 7.77 (m, 2H), 7.72 – 7.65 (m, 2H), 7.19 – 7.13 
(m, 2H), 7.10 – 7.05 (m, 2H), 3.88 – 3.71 (m, 2H), 3.32 (h, J = 7.3 Hz, 1H), 2.29 (s, 3H), 1.28 (d, J = 7.0 Hz, 
3H). 
 13
C NMR (101 MHz, CDCl3) δ 168.32, 140.26, 136.21, 133.81, 131.93, 129.14, 127.12, 123.16, 44.94, 
38.06, 21.00, 19.04. HRMS (ESI) calculated for  C18H17NO2 , 280.1332 found 280.1333 [M+H]
+
. IR (ATR-
FTIR) νmax = 2998, 2927, 2851, 2366, 2242, 1706, 1394, 1376, 1351 cm
-1
. HPLC: CHIRALPAK IA. 
Heptane/EtOH 50:50, 0.5 mL/min, λ = 210 nm. t(R) = 10.2 min, t(S) = 13.2 min. 
 
 
 
(R)-2-(2-(3-chlorophenyl)propyl)isoindoline-1,3-dione 
 
Following GP, the desired product was obtained as an oil  (full conversion, 99% ee). [α]D: +101.2 (c 1.3, 
CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.85 – 7.75 (m, 2H), 7.73 – 7.67 (m, 2H), 7.32 – 7.13 (m, 4H), 3.88 – 
3.73 (m, 2H), 3.32 (h, J = 7.3 Hz, 1H), 1.29 (d, J = 7.0 Hz, 3H). 
 13
C NMR (101 MHz, CDCl3) δ 168.21, 145.37, 
134.24, 133.94, 133.92, 131.82, 129.74, 127.56, 126.95, 125.46, 123.25, 44.57, 38.37, 18.83. HRMS (ESI) 
calculated for C17H14ClNO2 300.0786, found 300.0788 [M+H]
+
. IR (ATR-FTIR) νmax = 2957, 2971, 2850, 2361, 
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2337, 2245, 1711, 1396 cm
-1
. HPLC: CHIRALPAK IA. Heptane/EtOH 50:50, 0.5 mL/min, λ = 210 nm. t(R) = 
10.3 min, t(S) = 13.8 min. 
 
 
 
(R)-2-(2-(3-methoxyphenyl)propyl)isoindoline-1,3-dione 
 
Following GP, the desired product was obtained as an oil (full conversion, 98% ee). [α]D: +80.8 (c 1.3, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.83 – 7.77 (m, 2H), 7.72 – 7.65 (m, 2H), 7.19 (t, J = 7.9 Hz, 1H), 6.88 – 6.71 
(m, 3H), 3.90 – 3.77 (m, 2H), 3.76 (s, 3H), 3.33 (h, J = 7.3 Hz, 1H), 1.29 (d, J = 7.0 Hz, 3H). 
13
C NMR (101 
MHz, CDCl3) δ 168.29, 159.63, 144.97, 133.84, 131.91, 129.44, 123.18, 119.63, 112.91, 112.21, 55.14, 44.76, 
38.53, 18.97. HRMS (ESI) calculated for C18H17NO3 296.1281, found 296.1276 [M+H]
+
. IR (ATR-FTIR) νmax = 
3065, 2972, 2936, 2829, 1766, 1708, 1605, 1579, 1394, 1042 cm
-1
. HPLC: CHIRALPAK IA. Heptane/EtOH 
50:50, 0.5 mL/min, λ = 210 nm. t(R) = 10.9 min, t(S) = 17.1 min. 
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(R)-2-(2-(2-methoxyphenyl)propyl)isoindoline-1,3-dione 
 
Following GP, the desired product was obtained as an oil (full conversion, 78% ee). [α]D: +64.5 (c 1.3, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.78 (ddd, J = 5.5, 2.9, 0.4 Hz, 2H), 7.73 – 7.65 (m, 2H), 7.27 – 7.22 (m, 1H), 
7.20 – 7.11 (m, 1H), 6.91 (td, J = 7.5, 1.2 Hz, 1H), 6.74 (dd, J = 8.2, 1.1 Hz, 1H), 3.93 – 3.80 (m, 2H), 3.78 – 
3.71 (m, 1H), 3.64 (s, 3H), 1.30 (d, J = 6.9 Hz, 3H). 
 13
C NMR (101 MHz, CDCl3) δ 168.28, 157.28, 133.65, 
132.08, 131.52, 127.60, 127.49, 122.99, 120.62, 110.27, 55.11, 43.81, 31.98, 17.62. HRMS (ESI) calculated for 
C18H17NO3 296.1281, found 296.1281 [M+H]
+
. IR (ATR-FTIR) νmax = 2958, 2932, 2851, 1770, 1708, 1394, 
1242 cm
-1
. HPLC: CHIRALPAK IA. Heptane/EtOH 95:5, 0.5 mL/min, λ = 210 nm. t(R) = 15.8 min, t(S) = 16.9 
min. 
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(R)-2-(2-(o-tolyl)propyl)isoindoline-1,3-dione 
 
Following GP, using 3 mol% of catalyst and leaving the reaction stirring for 48 hours, the desired product was 
obtained as an oil (full conversion, 91% ee).  [α]D: +24.5 (c 0.5, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.86 – 
7.79 (m, 2H), 7.73 – 7.67 (m, 2H), 7.35 (dd, J = 7.6, 1.2 Hz, 1H), 7.21 (ddd, J = 7.7, 6.7, 2.5 Hz, 1H), 7.16 – 
7.08 (m, 2H), 3.87 – 3.73 (m, 2H), 3.69 – 3.56 (m, 1H), 2.40 (s, 3H), 1.26 (d, J = 6.9 Hz, 3H). 
13
C NMR (101 
MHz, CDCl3) δ 168.47, 141.51, 136.01, 133.90, 131.94, 130.42, 126.40, 126.26, 125.67, 123.20, 44.16, 33.64, 
19.39, 18.53. HRMS (ESI) calculated for C18H17NO2 280.1332, found 280.1343 [M+H]
+
. IR (ATR-FTIR) νmax = 
3461, 3065, 2967, 2923, 2856, 1775, 1706, 1394, 1350, 1276, 1042 cm
-1
. HPLC: CHIRALPAK IA. 
Heptane/EtOH 98:2, 0.5 mL/min, λ = 210 nm. t(R) = 16.5 min, t(S) = 18.1 min. 
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(R)-2-(2-(2-bromophenyl)propyl)isoindoline-1,3-dione 
 
Following GP and using 2 mol% of catalyst, the desired product was obtained as an oil (full conversion, 90% 
ee). [α]D: +47.2 (c 0.8, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.84 – 7.77 (m, 2H), 7.72 – 7.65 (m, 2H), 7.47 
(dd, J = 8.0, 1.4 Hz, 1H), 7.40 (dd, J = 7.8, 1.7 Hz, 1H), 7.31 (td, J = 7.6, 1.3 Hz, 1H), 7.05 (ddd, J = 8.0, 7.3, 1.7 
Hz, 1H), 3.95 – 3.86 (m, 2H), 3.85 – 3.77 (m, 1H), 1.33 – 1.27 (m, 3H). 
13
C NMR (101 MHz, CDCl3) δ 168.23, 
142.37, 133.85, 132.86, 131.93, 128.17, 127.78, 127.71, 124.79, 123.20, 43.67, 37.18, 18.57. HRMS (ESI) 
calculated for C17H14BrNO2 344.0281, found 344.0271 [M+H]
+
. IR (ATR-FTIR) νmax = 3466, 3056, 2963, 2923, 
2843, 1772, 1706, 1467, 1394, 1378, 1351, 1277, 1043, 1021 cm
-1
. HPLC: CHIRALPAK IA. Heptane/EtOH 
98:2, 0.5 mL/min, λ = 210 nm. t(R) = 27.3 min, t(S) = 30.6 min. 
 
 
 
 (R)-2-(2-(naphthalen-2-yl)propyl)isoindoline-1,3-dione 
 
Following GP, the desired product was obtained as a white solid (full conversion, 97% ee). m.p. 117-121 ºC 
[α]D: +66.1 (c 0.4, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ 7.81 – 7.74 (m, 5H), 7.71 – 7.63 (m, 3H), 7.49 – 7.38 
(m, 3H), 4.04 – 3.83 (m, 2H), 3.55 (h, J = 7.3 Hz, 1H), 1.39 (d, J = 7.0 Hz, 3H). 
13
C NMR (101 MHz, CDCl3) δ 
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140.77, 133.84, 133.46, 132.47, 131.88, 128.16, 127.64, 127.58, 125.91, 125.88, 125.87, 125.58, 125.43, 123.20, 
44.69, 38.67, 19.16. HRMS (ESI) calculated for  C21H17NO2 316.1332, found 316.1329 [M+H]
+
. IR (ATR-
FTIR) νmax = 3458, 3050, 2964, 2932, 2872, 1767,1705, 1682, 1397, 1048 cm
-1
. HPLC: CHIRALPAK IA. 
Heptane/EtOH 70:30, 0.5 mL/min, λ = 210 nm. t(R) = 13.5 min, t(S) = 20.6 min. 
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